By Adriano Marchese
Eli Lilly & Co. said Tuesday that it has launched new doses of its obesity treatment drug and reduced its prices.
The pharmaceutical company said it has launched 7.5 and 10 milligram single dose vials of its Zepbound drug, also known as tirzepatide, which join the existing lineup of 2.5 and 5 milligram as well as 10 and 12.5 milligram vials.
The company has also reduced the price through its Self Pay Journey program. The program reduces the price of the 7.5 mg and 10 mg doses to $499 per month from $599 and $699, respectively, at first fill and refills that occur within 45 days of prior delivery.
Eli Lilly's new price points and offerings are only through its proprietary LillyDirect Self Pay Pharmacy Solutions which the company said "enables a transparent price by removing third-party supply chain entities and allowing patients to access savings directly outside of insurance."
Zepbound, a dual receptor agonist obesity medication, reduces appetite and how much the recipient can eat, supporting other weight loss efforts such as reduced calorie diets and physical exercise.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
The pharmaceutical company said it has launched 7.5 and 10 milligram single-dose vials of its Zepbound drug, also known as tirzepatide, which join the existing lineup of 2.5 and 5 milligram vials. "Eli Lilly Introduces New Weight Loss Drug Doses, Lowers Price Points," at 7:21 a.m. incorrectly said Zepbound also comes in 10 and 12.5 milligram vials.
(END) Dow Jones Newswires
February 25, 2025 09:02 ET (14:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。